 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...3940414243444546474849...208209» |
- satricabtagene autoleucel (CT041) / CARsgen
Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01). (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2650;
P1/2
Satri-cel demonstrated significant PFS improvement and an obvious OS benefit with a manageable safety profile. These results support satri-cel as a potential new SOC for advanced G/GEJC.
- Aqupla (nedaplatin) / Simcere, Fruzaqla (fruquintinib) / Takeda, AiRuiKa (camrelizumab) / HLB Bio Group
Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 332) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2643;
P1/2
These results support satri-cel as a potential new SOC for advanced G/GEJC. The combination of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin demonstrated significant efficacy and manageable toxicity profile as a first-line treatment for advanced ESCC, suggesting a potential new treatment strategy.
- Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma: A multicenter real-world study. (Hall A - Posters and Exhibits; Poster Bd #: 408) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2641;
Locoregional combined with systemic therapy is an effective strategy for conversion treatment. Conversion surgery offers substantial survival benefits, while palliative surgery may also serve as a viable therapeutic option.
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II clinical trial. (Hall A - Posters and Exhibits; Poster Bd #: 328) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2640;
P4
Conversion surgery offers substantial survival benefits, while palliative surgery may also serve as a viable therapeutic option. As the first-line treatment for HER-2 negative advanced gastric and gastroesophageal junction adenocarcinoma, the combination of Carilizumab with albumin bound paclitaxel and S-1 has shown encouraging efficacy.
- AiRuiKa (camrelizumab) / HLB Bio Group
Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective single-arm phase II clinical trial. (Hall A - Posters and Exhibits; Poster Bd #: 347) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2603;
P1/2
As the first-line treatment for HER-2 negative advanced gastric and gastroesophageal junction adenocarcinoma, the combination of Carilizumab with albumin bound paclitaxel and S-1 has shown encouraging efficacy. The NRIT regimen is safe and feasible for patients with ESCC.
- Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases. (Hall A - Posters and Exhibits; Poster Bd #: 340) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2549;
P2
TACE followed by sintilimab, oxaliplatin and S-1 combined with either trastuzumab or apatinib demonstrated promising efficacy and manageable safety as first-line therapy for GCLM. Gastric cancer and its paired liver metastases exhibited distinct gene mutations and immune microenvironment.
- Stivarga (regorafenib) / Bayer
Efficacy and safety of regorafenib combination with PD-1 inhibitors vs. regorafenib monotherapy in second-line treatment for patients with unresectable hepatocellular carcinoma after failure of different first-line treatments: A multicenter retrospective real-world study. (Hall A - Posters and Exhibits; Poster Bd #: 378) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2521;
However, in patients who have progressed after first-line TKI plus PD-1 therapy, using regorafenib alone or in combination with PD-1 in second-line therapy does not show a significant difference in efficacy. These findings have significant implications for the selection of second-line treatment strategies for HCC patients, indicating that the combination of regorafenib and PD-1 might not provide additional benefits in certain patient subgroups.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study. (Hall A - Posters and Exhibits; Poster Bd #: 383) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2495;
P1/2, P3
A more favorable benefit-risk profile was observed for SHR-8068 given as a priming dose. A phase 3 trial (NCT06618664) is currently underway to further assess the combination as 1L treatment for aHCC.
- Sulanda (surufatinib) / Hutchmed, AiRuiKa (camrelizumab) / HLB Bio Group
First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study. (Hall A - Posters and Exhibits; Poster Bd #: 451) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2474;
P1/2
The NASCA regimen demonstrated promising efficacy with a manageable safety profile, showing a significantly higher ORR and longer PFS compared to AG group in patients with locally advanced or metastatic PDAC. Further studies are warranted to confirm these findings.
- SHR-A2102 / Jiangsu Hengrui Pharma
Phase 1 trial of SHR-A2102, a nectin-4 (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2269;
P1
Multiple trials are ongoing to further assess SHR-A2102 both as monotherapy and in combination therapy for solid tumors. Efficacy in selected tumor types (efficacy evaluable set).*Include responses to be confirmed.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Granisetron transdermal delivery system for nausea and vomiting prophylaxis in HER2-positive metastatic breast cancer patients receiving pyrotinib and capecitabine: A single-arm phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 89) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2213;
P2
Prolonged administration of GTDS demonstrated efficacy and safety in preventing nausea and vomiting in HER2-positive mBC patients receiving daily oral pyrotinib and capecitabine; however, it did not reduce the incidence of ? grade 3 diarrhea.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Phase Ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma. (Hall A - Posters and Exhibits; Poster Bd #: 16) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2059;
P2
Part 2 to evaluate safety and efficacy is currently recruiting pts. TRAEs with an incidence of ?30% and any grade ?3 TRAEs.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2025;
P2
The combination of camrelizumab and apatinib demonstrated promising efficacy and manageable toxicity in chordoma treatment. Furthermore, CDKN2A alterations (CND or HD) were associated with poorer outcomes, providing a potential biomarker for therapeutic stratification.
- Keytruda (pembrolizumab) / Merck (MSD), plinabulin (BPI 2358) / BeyondSpring
Phase 2 study of pembrolizumab (pembro) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after progression on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on immune re-sensitization. (Hall A - Posters and Exhibits; Poster Bd #: 40) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1797;
P2
The AEs of the triple combination treatment is manageable. Further investigations into which pts would benefit from continued ICI treatment after progression is warranted.
- Efficacy of immune checkpoint inhibitors (ICIs) in advanced large cell neuroendocrine carcinoma (LCNEC) of the lung: A systematic review and meta-analysis. (Hall A - Posters and Exhibits; Poster Bd #: 56) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1755;
ICIs, based on our meta-analysis, have also demonstrated encouraging results in advanced LCNEC. However, tumor factors such as molecular subtypes, genomic profiles, and other predictors influencing the response to ICIs need to be elucidated.
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with 2 cycles of chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC): A two-arm, single-center, phase 2 study. (Hall A - Posters and Exhibits; Poster Bd #: 28) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1718;
P2
However, the 4-cycle platinum-based chemotherapy group may have resulted in a higher probability of developing grade ?3 treatment-related adverse events. A combination of a 2-cycle chemotherapy and immunotherapy may be more suitable for elderly patients with advanced lung cancer.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in patients with unresectable advanced metastatic or recurrent thymic carcinomas. (Hall A - Posters and Exhibits; Poster Bd #: 230) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1616;
P2
In previously untreated advanced TCs, preliminary results showed that adebrelimab plus nab-paclitaxel and carboplatin is effective and safe. It provides a new treatment option in pts with advanced TCs.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety results. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1505;
P2
SHR-A1811 demonstrated promising efficacy in both HER2-positive and HER2-low advanced salivary gland cancers, achieving high ORRs and DCRs with an acceptable toxicity profile. Baseline characteristics.
- Gilotrif (afatinib) / Boehringer Ingelheim
Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): An open-label, single-arm, phase 2 study. (Hall A - Posters and Exhibits; Poster Bd #: 477) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1499;
P2
This study firstly reported the promising efficacy and acceptable safety profile of neoadjuvant chemoimmunotherapy combined with apatinib in the treatment of patients with LA-HNSCC. Further evaluation in large-scale clinical trials with longer follow-up periods is needed.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 442) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1495;
P2
In terms of head and neck squamous cell carcinoma, Phase I clinical studies have confirmed the therapeutic safety and tumor activity of PD-L1 inhibitors. In this Phase II study, the PD-L1 inhibitor (Adebrelimab) demonstrated a favorable therapeutic response to locally advanced head and neck squamous cell carcinoma, and we look forward to final therapeutic data.
- AiTan (rivoceranib) / HLB Bio Group, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, AiRuiKa (camrelizumab) / HLB Bio Group
Major pathological response to neoadjuvant immune-related therapy and influence on long-term survival in patients with locally advanced oral squamous cell carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 450) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1467;
P1
Two single-arm trials were included in this study on NAIT of neoadjuvant immunochemotherapy (NAICT) with Toripalimab plus albumin paclitaxel/cisplatin (NCT04473716) or neoadjuvant immunotarget therapy (NAITT) with Camrelizumab plus Apatinib (NCT04393506) in LAOSCC patients at clinical stage III and IVA (AJCC 2018). NAICT and NAITT are safe and effective, the LAOSCC patients with CPS>10 or archiving MPR could have long-term survival benefit from NAIT.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Erbitux (cetuximab) / Eli Lilly
Cetuximab plus dalpiciclib in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 434) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1455;
P2
NAICT and NAITT are safe and effective, the LAOSCC patients with CPS>10 or archiving MPR could have long-term survival benefit from NAIT. Dalpiciclib combined with cetuximab was well-tolerated and demonstrated potentially favorable efficacy in patients with anti-PD-1-resistant, HPV-negative R/M HNSCC.
- Erbitux (cetuximab) / Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): 1-year outcomes from the phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 438) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1449;
P2
Further evaluation including a phase III study is warranted. Demographics and baseline characteristics.
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Retlirafusp alfa-a bifunctional anti-PD-L1/TGF-?RII agent plus nab-paclitaxel and carboplatin in pre-treated recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, phase II clinical trial. (Hall A - Posters and Exhibits; Poster Bd #: 437) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1409;
P2
Even as most pts have progressed on ICIs before enrollment, retlirafusp alfa plus nab-paclitaxel and carboplatin demonstrated promising anti-tumor efficacy and manageable toxicities in pre-treated R/M HNSCC. Long-term efficacy needs to be confirmed by further follow-up.
- SHR-1501 / Jiangsu Hengrui Pharma
IL-15R?Fc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study. (Hall A - Posters and Exhibits; Poster Bd #: 406) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1241;
P1/2
Long-term efficacy needs to be confirmed by further follow-up. SHR-1501 alone or in combination with BCG was well-tolerable and demonstrated a favorable efficacy in BCG-naive and BCG-unresponsive high-risk NMIBC pts, supporting further investigations.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Biomarkers of neoadjuvant dalpiciclib in patients with operable HER2-negative luminal B breast cancer in the DANCER trial. (Hall A - Posters and Exhibits; Poster Bd #: 193) - Apr 23, 2025 - Abstract #ASCO2025ASCO_779;
P2
SHR-1501 alone or in combination with BCG was well-tolerable and demonstrated a favorable efficacy in BCG-naive and BCG-unresponsive high-risk NMIBC pts, supporting further investigations. Patients with operable HER2-negative luminal B breast cancer who exhibit early ctDNA clearance, MammaPrint low-risk status, GSTM1 deletion, increased pRb/CDK4 expression, and higher plasma CCL4/CCL19 levels may derive substantial benefit from neoadjuvant dalpiciclib therapy.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2 (Hall B1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_676;
P3
These data support the use of Dalp for treating HR+/HER2- early BC. Efficacy outcomes.*Kaplan
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
Enrollment open: Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Apr 22, 2025
P3, N=682, Recruiting, Sponsor: Zuoyi Jiao
Efficacy outcomes.*Kaplan Not yet recruiting --> Recruiting
- | HRS-4642 / Jiangsu Hengrui Pharma
New P2 trial: An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer (clinicaltrials.gov) - Apr 21, 2025
P2, N=60, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Pathologically Complete Response to Camrelizumab and Apatinib in Advanced Cervical Cancer with PTEN, PIK3CA, MTOR, and ARID1A Mutations: A Case Report. (Pubmed Central) - Apr 21, 2025
Camrelizumab is affordable, at just 10% of the price of pembrolizumab, although it is similarly not covered by medical insurance for cervical cancer in China. The PTEN, PIK3CA, MTOR, and ARID1A gene mutations hold the potential to serve as predictive biomarkers for cervical cancer patients treated by PD-1 inhibitors.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Clinical, Retrospective data, Journal: Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study. (Pubmed Central) - Apr 21, 2025
Neither group recorded any adverse event-related deaths. Pyrotinib plus capecitabine significantly improves median PFS compared to T-DM1 in patients with HER2-positive advanced breast cancer, demonstrating a favorable efficacy profile alongside manageable safety concerns.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Erbitux (cetuximab) / Eli Lilly
New P2 trial: Dawn-01: Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC (clinicaltrials.gov) - Apr 21, 2025
P2, N=98, Recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- SHR-1816 / Jiangsu Hengrui Pharma
Enrollment change, Trial termination: Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects (clinicaltrials.gov) - Apr 21, 2025
P1, N=60, Terminated, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Pyrotinib plus capecitabine significantly improves median PFS compared to T-DM1 in patients with HER2-positive advanced breast cancer, demonstrating a favorable efficacy profile alongside manageable safety concerns. N=96 --> 60 | Not yet recruiting --> Terminated; Sponsor internal strategy change.
- |||||| Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811-307: A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 21, 2025
P3, N=864, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=96 --> 60 | Not yet recruiting --> Terminated; Sponsor internal strategy change. Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib Inhibits HTNV by Stimulating TFEB-Driven Lysosome Biogenesis to Degrade Viral Protein. (Pubmed Central) - Apr 19, 2025
Consequently, there is an increase in lysosome-mediated viral nucleocapsid protein degradation. The ability of apatinib to stimulate this lysosome-driven antiviral mechanism presents a potential new therapeutic approach for viral infections and offers valuable insights into virus-host interactions during HTNV replication.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Reimbursement, US reimbursement, Journal: Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis. (Pubmed Central) - Apr 18, 2025
The GRN policy improved the accessibility and affordability of PD-1 drugs. Health insurance policy-makers need to consider the legitimate interests of PD-1 drug manufacturers while ensuring the sustainability of the basic health insurance fund.
- | carboplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
Journal: Synchronous triple squamous cell carcinomas of the stomach, skin and gingiva with liver, lung, spleen, kidney, bone and brain metastases: A case report. (Pubmed Central) - Apr 17, 2025
In the present case, a diagnosis of triple primary SCCs of the skin, stomach and gingiva with multiple organ metastases was made based on epidemiologic features and clinical presentation. The results of the present case report suggested that anti-programmed death 1 antibodies combined with platinum-based chemotherapy may be a treatment option for metastatic SCC.
- | AiTan (rivoceranib) / HLB Bio Group
Phase classification, Enrollment change: Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II?Multi-center, Clinical Study. (clinicaltrials.gov) - Apr 17, 2025
P1/2, N=125, Recruiting, Sponsor: Sun Yat-sen University
The results of the present case report suggested that anti-programmed death 1 antibodies combined with platinum-based chemotherapy may be a treatment option for metastatic SCC. Phase classification: P2 --> P1/2 | N=62 --> 125
- |||| SHR-1826 / Jiangsu Hengrui Pharma
Enrollment open: A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (clinicaltrials.gov) - Apr 17, 2025
P1/2, N=400, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase classification: P2 --> P1/2 | N=62 --> 125 Not yet recruiting --> Recruiting
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
P2 data, Journal, Combination therapy, Metastases: Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer After Trastuzumab Failure (PROVE): A Prospective Phase 2 Study. (Pubmed Central) - Apr 17, 2025
Not yet recruiting --> Recruiting Pyrotinib combined with metronomic vinorelbine showed promising efficacy and an acceptable safety profile in HER2-positive advanced breast cancer patients after trastuzumab failure.
- | Itari (linperlisib) / Shanghai YingLi Pharma
Journal: KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T (Pubmed Central) - Apr 16, 2025
P1
inhibitor) for refractory cases, 7 of 8 participants quickly respond with satisfactory safety. This study is registered at ClinicalTrials.gov (NCT05676710).
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Precision treatment for human epidermal growth factor receptor 2-amplified advanced rectal cancer: A case report. (Pubmed Central) - Apr 16, 2025
ICIs and pyrotinib may be effective in treating HER2-amplified advanced rectal cancer. Chemotherapy following disease progression could enhance efficacy synergistically.
- ||||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. (clinicaltrials.gov) - Apr 16, 2025
P3, N=213, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Chemotherapy following disease progression could enhance efficacy synergistically. Not yet recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Mar 2025
- |||||||||| SHR-A1912 / Jiangsu Hengrui Pharma
New P3 trial: A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Apr 16, 2025
P3, N=280, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Tabosun (ipilimumab N01 injection) / Innovent Biologics
Enrollment closed, Trial completion date: PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment (clinicaltrials.gov) - Apr 16, 2025
P2, N=40, Active, not recruiting, Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Mar 2025 Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Sep 2025
- HXN-1011 / Earendil Labs
AI-Guided Design and Development of HXN-1011: A Potent Anti-TSLP Biparatopic Antibody (Carron 1) - Apr 15, 2025 - Abstract #EAACI2025EAACI_2332;
Results Epitope mapping confirmed that HXN-1011 simultaneously binds to both Site I and Site II, while other TSLP antibodies, including Tezepelumab (AstraZeneca), GSK5784283 (GSK/Hengrui), and CM326 (Keymed), bind only to Site I. HXN-1011 exhibited a binding affinity approximately 100-fold higher than Tezepelumab and achieved IC90 values 15- to 100-fold lower in functional assays...HXN-1011 also showed superior efficacy across all tested parameters in OVA+MC903-induced lung and skin inflammation...Conclusion HXN-1011 is a next-generation biparatopic antibody with exceptional potency and significant potential to improve clinical efficacy in treating TSLP-driven inflammatory diseases, such as asthma, COPD, and beyond. Preclinical studies and IND-enabling research for HXN-1011 are currently in progress.
- || Clinical, Retrospective data, Review, Journal: The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study. (Pubmed Central) - Apr 15, 2025
We produced high-quality evidence on the comparative effectiveness of monotherapies for AA with various regimens of 8 JAKIs, including the FDA-approved ones. Our findings can improve clinicians' decision-making and update guidelines for medical practice.
- |||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Apr 15, 2025
P3, N=100, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Our findings can improve clinicians' decision-making and update guidelines for medical practice. Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> Dec 2024
- || M9466 / EMD Serono
Trial completion date, Trial primary completion date, Monotherapy: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 15, 2025
P1, N=153, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> Dec 2024 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment closed, Enrollment change, Trial primary completion date: SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov) - Apr 15, 2025
P2, N=76, Active, not recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026 N=258 --> 76 | Trial primary completion date: Jul 2026 --> Apr 2025 | Recruiting --> Active, not recruiting